Key result
SGLT2 inhibitors reduce HF hospitalization in HFpEF patients per rural Australian guidelines.
Why the study?
While HFpEF has had few proven treatments, recent trials showed SGLT2 inhibitors significantly reduce HF hospitalizations in HFpEF, now supported by guidelines.
There is a significant disparity in heart failure and diabetes hospitalizations between remote/rural areas and major cities in Australia, necessitating improved healthcare access and workforce.
Answers are grounded in this paper and cite their sources.
Highlights urgent need for SGLT2i access amid rural HF disparities; leaves open implementation effectiveness in remote Australian settings.
Background: Heart failure (HF) patients with a ‘reduced’ ejection fraction (HFrEF) have several proven treatment options, but for those with a ‘preserved’ ejection fraction (HFpEF) there are very few. However, recent trials such as the EMPEROR-Preserved and DELIVER have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce HF hospitalization in HFpEF patients, and these are now supported by both Australian and international guidelines. Methods: We undertook a narrative review using a structured multi-database search (MEDLINE, Embase, CINAHL, Scopus) and key Australian sources (AIHW, ABS, Department of Health and Aged Care) without geographic or publication-year restrictions. Results: In Australia there were approximately 179,000 hospitalizations in 2020–2021 due to HF equating to a rate of 697 per 100,000 population. The age-standardized hospitalization rate for HF in remote and very remote areas was 1.8 times higher than in major cities. Likewise, since 2000 the prevalence of diabetes has nearly tripled, from 460,000 to 1.3 million. In remote areas, there were 47,600 diabetes hospitalizations in 2021–2022, with residents being 2.5 times more likely to be hospitalized for diabetes compared to those in major cities. Conclusions: In rural Australia, reducing preventable hospitalizations and premature mortality from heart failure and type 2 diabetes requires a stronger rural generalist and general practitioner workforce, improved access to essential medicines and telehealth, and equity-focused evaluation.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2025) studied this question. SGLT2 inhibitors significantly reduce HF hospitalization in HFpEF patients, supported by guidelines in rural Australia amid rising diabetes prevalence.
Synapse has enriched 10 related papers. Consider them for comparative context: